Zobrazeno 1 - 10
of 678
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Ming Zhao, Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans, Fei Yang, Argun Akcakanat, Marco Roberto Estecio, Debu Tripathy, Ecaterina E. Dumbrava, Senthil Damodaran, Funda Meric-Bernstam
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-14 (2023)
Abstract TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression. In metaplastic breast cancers (MpBC), there is limited expression of TROP2
Externí odkaz:
https://doaj.org/article/153c2e942072429c8da59c33c6ea4273
Autor:
Bikash Panthi, Rania M. Mohamed, Beatriz E. Adrada, Medine Boge, Rosalind P. Candelaria, Huiqin Chen, Kelly K. Hunt, Lei Huo, Ken-Pin Hwang, Anil Korkut, Deanna L. Lane, Huong C. Le-Petross, Jessica W. T. Leung, Jennifer K. Litton, Sanaz Pashapoor, Frances Perez, Jong Bum Son, Jia Sun, Alastair Thompson, Debu Tripathy, Vicente Valero, Peng Wei, Jason White, Zhan Xu, Wei Yang, Zijian Zhou, Clinton Yam, Gaiane M. Rauch, Jingfei Ma
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Early prediction of neoadjuvant systemic therapy (NAST) response for triple-negative breast cancer (TNBC) patients could help oncologists select individualized treatment and avoid toxic effects associated with ineffective therapy in patients unlikely
Externí odkaz:
https://doaj.org/article/ce05b7a736b747c6b99c4058b0f5d015
Autor:
Hui Chen, Qingqing Ding, Laila Khazai, Li Zhao, Senthil Damodaran, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz Adrada, Kiran Virani, Jason B. White, Elizabeth Ravenberg, Xingzhi Song, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Mark J. Routbort, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Wei-Lien Wang, Stacy Moulder, Lei Huo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Recent advances have been made in targeting the phosphoinositide 3-kinase pathway in breast cancer. Phosphatase and tensin homolog (PTEN) is a key component of that pathway. Objective: To understand the changes in PTEN expression over the
Externí odkaz:
https://doaj.org/article/d6308ee798424003bf82ce6d0277871d
Autor:
Zijian Zhou, Beatriz E. Adrada, Rosalind P. Candelaria, Nabil A. Elshafeey, Medine Boge, Rania M. Mohamed, Sanaz Pashapoor, Jia Sun, Zhan Xu, Bikash Panthi, Jong Bum Son, Mary S. Guirguis, Miral M. Patel, Gary J. Whitman, Tanya W. Moseley, Marion E. Scoggins, Jason B. White, Jennifer K. Litton, Vicente Valero, Kelly K. Hunt, Debu Tripathy, Wei Yang, Peng Wei, Clinton Yam, Mark D. Pagel, Gaiane M. Rauch, Jingfei Ma
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Neoadjuvant systemic therapy (NAST) followed by surgery are currently standard of care for TNBC with 50-60% of patients achieving pathologic complete response (p
Externí odkaz:
https://doaj.org/article/9d1afc4d0a46451ea11ba6d0e3bea0a2
Autor:
Jason A. Mouabbi, Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Hassan, Debu Tripathy, Rachel M. Layman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC). However, it is unknown whether patients with invasive lobular carcinoma (
Externí odkaz:
https://doaj.org/article/982f3e9cb56b48ee9ecd4add8542b9a0
Autor:
Zhan Xu, David E. Rauch, Rania M. Mohamed, Sanaz Pashapoor, Zijian Zhou, Bikash Panthi, Jong Bum Son, Ken-Pin Hwang, Benjamin C. Musall, Beatriz E. Adrada, Rosalind P. Candelaria, Jessica W. T. Leung, Huong T. C. Le-Petross, Deanna L. Lane, Frances Perez, Jason White, Alyson Clayborn, Brandy Reed, Huiqin Chen, Jia Sun, Peng Wei, Alastair Thompson, Anil Korkut, Lei Huo, Kelly K. Hunt, Jennifer K. Litton, Vicente Valero, Debu Tripathy, Wei Yang, Clinton Yam, Jingfei Ma
Publikováno v:
Cancers, Vol 15, Iss 19, p 4829 (2023)
Accurate tumor segmentation is required for quantitative image analyses, which are increasingly used for evaluation of tumors. We developed a fully automated and high-performance segmentation model of triple-negative breast cancer using a self-config
Externí odkaz:
https://doaj.org/article/13a3720095084e2faf7f2ac9d1c1eb92
Autor:
Haven R. Garber, Akshara Singareeka Raghavendra, Michael Lehner, Wei Qiao, Angelica M. Gutierrez-Barrera, Debu Tripathy, Banu Arun, Nuhad K. Ibrahim
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)
Abstract Patients with hereditary mutations in BRCA1 or BRCA2 (gBRCA1/2) and breast cancer have distinct tumor biology, and encompass a predilection for brain metastasis (BM). We looked into baseline risk of BMs among gBRCA1/2 patients. Patients with
Externí odkaz:
https://doaj.org/article/f030913dffdd4ede9b5d864d22d62e01
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Nour Abuhadra, Ryan Sun, Clinton Yam, Gaiane M. Rauch, Qingqing Ding, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz E. Adrada, Senthil Damodaran, Kiran Virani, Jason White, Elizabeth Ravenberg, Jia Sun, Jaihee Choi, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Jennifer K. Litton, Debu Tripathy, Stacy Moulder, Lei Huo
Publikováno v:
Cancers, Vol 15, Iss 13, p 3275 (2023)
High stromal tumor-infiltrating lymphocytes (sTILs) are associated with improved pathologic complete response (pCR) in triple-negative breast cancer (TNBC). We hypothesize that integrating high sTILs and additional clinicopathologic features associat
Externí odkaz:
https://doaj.org/article/27f5149e61a341b7a9347399b211d86d
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8